MedTrace Logo

Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)

NCT00812864 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-08-28

No results posted yet for this study

Summary

The aim of the study is to determine blood concentration evolution of capecitabine and its active metabolites, in elderly patient 75 years and more.

Conditions

Interventions

DRUG

Capecitabine

Pharmacokinetic of its metabolites. Capecitabine, 1250 mg/m2 twice a day

Sponsors & Collaborators

  • University Hospital, Limoges

    lead OTHER

Principal Investigators

  • Nicole TUBIANA-MATHIEU, MD · CHU de Limoges, medical oncology department ,02 avenue Martin Luther King 87042 Limoges cedex France

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-10-31
Completion
2012-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812864 on ClinicalTrials.gov